User:Mr. Ibrahem/Asciminib

Asciminib, sold under the brand name Scemblix, is a medication used to treat chronic myeloid leukemia which is Philadelphia chromosome-positive (Ph+ CML). It is used when other medications have failed. It is taken by mouth twice per day.

Common side effects include upper respiratory tract infections, musculoskeletal pain, headache, tiredness, nausea, rash, and diarrhea. Other side effects may include bone marrow suppression, pancreatitis, high blood pressure, allergic reactions, and heart disease. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor specifically of the BCR::ABL1 tyrosine kinase.

Asciminib was approved for medical use in the United States in 2021 and Europe in 2022. In the United Kingdom its costs the NHS for 30 days at 40 mg twice per day £4050 as of 2022. In the United States this amount costs about 18,500 USD.